TCGA-C8-A132-01A-31R-A115-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 13
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- ALLOGRAFT_REJECTION+0.410
- HEDGEHOG_SIGNALING+0.400
- TGF_BETA_SIGNALING+0.370
- KRAS_SIGNALING_UP+0.350
- WNT_BETA_CATENIN_SIGNALING+0.350
- UV_RESPONSE_DN+0.340
- APICAL_JUNCTION+0.330
- IL6_JAK_STAT3_SIGNALING+0.320
- COMPLEMENT+0.300
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.500
- OXIDATIVE_PHOSPHORYLATION-0.430
- E2F_TARGETS-0.400
- MYC_TARGETS_V2-0.380
- ADIPOGENESIS-0.330
- DNA_REPAIR-0.310
- PEROXISOME-0.310
- CHOLESTEROL_HOMEOSTASIS-0.260
- FATTY_ACID_METABOLISM-0.260
- BILE_ACID_METABOLISM-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a307b24f-4caa-403a-8313-2a4604f2079a | — | — | 0.890 |
| 2 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.880 |
| 3 | TCGA-A2-A25A-01A-12R-A16F-07 | — | A | 0.878 |
| 4 | 67be8235-7f6f-4c36-9ad7-c72f8308fb52 | — | — | 0.877 |
| 5 | ec054d40-e5b8-496a-8c99-5e7f88f2cf37 | — | — | 0.877 |
| 6 | 80cb0e05-387d-4bd8-b49c-ff2aae043982 | — | — | 0.875 |
| 7 | SRR10900557 | — | — | 0.870 |
| 8 | BSR_03_0038_A2_S89 | — | A | 0.869 |
| 9 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.869 |
| 10 | 21196229-e39e-4846-be58-a1055b3ae50e | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |